Diabetes: Bariatric Surgery Beats GLP-1 Drugs for Heart Health, Study Finds

Top Summary

• What happened: A meta-analysis reveals metabolic and bariatric surgery (MBS) provides superior long-term cardiovascular protection compared to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes patients with obesity.
• Why it matters: This challenges current treatment strategies, suggesting surgery might be a more effective option for reducing major adverse cardiovascular events (MACEs) and all-cause mortality.
• What changes: Doctors may reconsider surgery as a first-line treatment for obese patients with type 2 diabetes to improve long-term cardiovascular outcomes.
• Who is affected: Obese individuals with type 2 diabetes, clinicians treating these patients, and healthcare systems evaluating treatment costs and benefits.

MBS vs. GLP-1 RAs: A New Look at Heart Health

Metabolic and bariatric surgery (MBS) shows greater promise in protecting against cardiovascular issues than glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This is according to a new study published in Obesity Surgery.

Joshua Chadwick from the Indian Council of Medical Research, along with his team, analyzed data from 11 studies. This included nearly 20,000 patients.

The research compared the effectiveness of MBS and GLP-1 RAs in reducing major adverse cardiovascular events (MACEs) and all-cause mortality.

Key Findings: Surgery's Edge

The study revealed a significant difference between the two treatment approaches. MBS showed a 52% relative risk reduction for MACEs and all-cause mortality compared to GLP-1 RA therapy.

This benefit held true across various study types, including randomized controlled trials (RCTs) and observational cohorts. A sensitivity analysis further validated these findings.

The most common MBS procedures were Roux-en-Y gastric bypass and sleeve gastrectomy. Commonly prescribed GLP-1 drugs included semaglutide (Wegovy, Ozempic), liraglutide (Saxenda, VIctosa), and dulaglutide (Trulicity).

The Multifactorial Benefits of Surgery

Researchers emphasized that the advantages of MBS go beyond just controlling blood sugar and losing weight.

"The observed benefits of MBS extend beyond glycemic control and weight loss, likely reflecting the multifactorial impact of surgical interventions on metabolic and cardiovascular risk factors,"

the authors wrote.

 

The study suggests that surgical interventions have a broader positive impact on overall metabolic and cardiovascular health.

GLP-1 RAs: Still a Valuable Option

The authors clarified that GLP-1 RAs remain important.

"GLP-1 RAs remain an essential therapeutic option for patient's ineligible for surgery or seeking non-surgical management, though weight regain and long-term cardiovascular outcomes warrant careful consideration,"

they stated.

 

GLP-1 RAs are still beneficial, particularly for those who cannot undergo surgery or prefer non-surgical approaches. However, the study highlights the potential long-term cardiovascular advantages of MBS.

Individualized Treatment Approaches

The study underscores the need for personalized treatment plans.

"Clinicians should individualize therapy based on patient risk profiles, preferences and access, with future research needed to clarify the optimal sequencing and combination of interventions, long-term safety and cost-effectiveness in real-world practice."

 

Treatment decisions should consider individual patient factors. Future research is needed to optimize treatment strategies.

What to Watch Next

Future studies should focus on determining the best sequence and combination of treatments, as well as long-term safety and cost-effectiveness. Real-world application and outcomes need further examination to refine clinical guidelines and improve patient care.